Importer of Controlled Substances; Notice of Application; NORAMCO, Inc., 51747 [2013-20285]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 162 / Wednesday, August 21, 2013 / Notices
stationery. Requests should identify the
name, title, and company or other
organizational affiliation (if any),
address, telephone number, email
address, and industry or main line of
business of the company, if any, of the
person signing the request letter and of
the persons who plan to appear at one
or both hearings. Requests to appear
may be made by mail or delivered in
person to the Commission’s Office of the
Secretary (see ADDRESSES), or may be
filed by email sent to SMEHearing@
usitc.gov. The Commission does not
accept requests filed by fax.
Written Submissions: In lieu of or in
addition to participating in the hearing,
interested parties are invited to file
written submissions concerning this
investigation. Such submissions should
be addressed to the secretary, and
should be received no later than 5:15
p.m., October 15, 2013. All written
submissions must conform to the
provisions of section 201.8 of the
Commission’s Rules of Practice and
Procedure (19 CFR 201.8). Section 201.8
and the Commission’s Handbook on
Filing Procedures require that interested
parties file documents electronically on
or before the filing deadline and submit
eight (8) true paper copies by 12:00 p.m.
eastern time on the next business day.
In the event that confidential treatment
of a document is requested, interested
parties must file, at the same time as the
eight paper copies, at least four (4)
additional true paper copies in which
the confidential information must be
deleted (see the following paragraph for
further information regarding
confidential business information).
Persons with questions regarding
electronic filing should contact the
Secretary (202–205–2000).
Any submissions that contain
confidential business information (CBI)
must also conform to the requirements
of section 201.6 of the Commission’s
Rules of Practice and Procedure (19 CFR
201.6). Section 201.6 of the rules
requires that the cover of the document
and the individual pages be clearly
marked as to whether they are the
‘‘confidential’’ or ‘‘non-confidential’’
version, and that the confidential
business information is clearly
identified by means of brackets. All
written submissions, except for
confidential business information, will
be made available for inspection by
interested parties.
In the request letter, the USTR stated
that the Office of the USTR intends to
make the Commission’s report available
to the public in their entirety, and asked
that the Commission not include any
confidential business information or
national security classified information
VerDate Mar<15>2010
16:29 Aug 20, 2013
Jkt 229001
in the report that the Commission sends
to the USTR. Any confidential business
information received by the
Commission in this investigation and
used in preparing this report will not be
published in a manner that would
reveal the operations of the firm
supplying the information.
By order of the Commission.
Issued: August 16, 2013
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013–20388 Filed 8–20–13; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; NORAMCO, Inc.
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on June 27, 2013, Noramco, Inc.,
1440 Olympic Drive, Athens, Georgia
30601, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
the basic classes of controlled
substances:
Drug
Schedule
Phenylacetone (8501) ..................
Thebaine (9333) ...........................
Poppy Straw Concentrate (9670)
Tapentadol (9780) ........................
II
II
II
II
The company plans to import
Thebaine (9333) analytical standards for
distribution to its customers. The
company plans to import an
intermediate form of Tapentadol (9780)
to bulk manufacture Tapentadol for
distribution to its customers. The
company plans to import the
Phenylacetone (8501) in bulk for the
manufacture of a controlled substance.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
In reference to the non-narcotic raw
material, any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
51747
to 21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 20, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: August 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–20285 Filed 8–20–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (BJA) Docket No. 1629]
Meeting of the Department of Justice’s
(DOJ’s) National Motor Vehicle Title
Information System (NMVTIS) Federal
Advisory Committee
Office of Justice Programs
(OJP), Justice.
ACTION: Notice of meeting.
AGENCY:
This is an announcement of a
meeting of DOJ’s National Motor
Vehicle Title Information System
(NMVTIS) Federal Advisory Committee
to discuss various issues relating to the
operation and implementation of
NMVTIS.
DATES: The meeting will take place on
Tuesday October 8, 2013, from 10:00
a.m. to 4:00 p.m. ET.
ADDRESSES: The meeting will take place
at the Office of Justice Programs (OJP),
810 7th Street NW., Washington, DC
20531.
FOR FURTHER INFORMATION CONTACT:
Todd Brighton, Designated Federal
Employee (DFE), Bureau of Justice
SUMMARY:
E:\FR\FM\21AUN1.SGM
21AUN1
]]>Agencies
[Federal Register Volume 78, Number 162 (Wednesday, August 21, 2013)]
[Notices]
[Page 51747]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-20285]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application;
NORAMCO, Inc.
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this
is notice that on June 27, 2013, Noramco, Inc., 1440 Olympic Drive,
Athens, Georgia 30601, made application by renewal to the Drug
Enforcement Administration (DEA) for registration as an importer of the
basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Phenylacetone (8501)....................... II
Thebaine (9333)............................ II
Poppy Straw Concentrate (9670)............. II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to import Thebaine (9333) analytical standards
for distribution to its customers. The company plans to import an
intermediate form of Tapentadol (9780) to bulk manufacture Tapentadol
for distribution to its customers. The company plans to import the
Phenylacetone (8501) in bulk for the manufacture of a controlled
substance.
Comments and requests for hearings on applications to import
narcotic raw material are not appropriate. 72 FR 3417 (2007).
In reference to the non-narcotic raw material, any bulk
manufacturer who is presently, or is applying to be, registered with
DEA to manufacture such basic classes of controlled substances listed
in schedules I or II, which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than September 20, 2013.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substances
in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: August 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-20285 Filed 8-20-13; 8:45 am]
BILLING CODE 4410-09-P
